Lineage Cell Therapeutics, Inc. 8-K

What Happened Lineage Cell Therapeutics, Inc. (LCTX) filed an 8-K on March 11, 2026 announcing a prospectus supplement (dated March 11, 2026) to its shelf registration on Form S-3. The supplement covers the offer and sale of up to $60,000,000 in common shares through an at-the-market (ATM) sales agreement with B. Riley Securities, Inc., pursuant to the company’s Registration Statement (File No. 333-277758) that was declared effective May 14, 2024. The filing also attaches a legal opinion from Sheppard, Mullin, Richter & Hampton LLP.

Key Details

• Prospectus supplement dated March 11, 2026; sales agreement with B. Riley dated March 22, 2024.
• ATM offering capacity: up to $60,000,000 in common shares (excluding $22,583,663.82 already sold under prior supplements/base prospectus).
• Shares to be sold “from time to time” through B. Riley under the Form S-3 shelf registration.
• Legal opinion of Sheppard, Mullin included as Exhibit 5.1 to the filing.

Why It Matters This filing gives Lineage a flexible mechanism to raise capital over time by selling common shares into the market, which can help fund operations, development programs, or other corporate needs without a single large offering. Any sales under the ATM would increase the number of outstanding shares and could dilute existing shareholders’ ownership; the company has not committed to sell any specific amount immediately. Investors should monitor future 8-Ks or 10-Q/10-K disclosures for actual ATM sales and proceeds.